The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

Zepbound comes as a solution for injection under the skin (subcutaneous). It’s typically used once per week. The Food and Drug Administration (FDA) has approved Zepbound to: help with weight ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Weekly subcutaneous administration of sabirnetug ... of biologics that can be delivered subcutaneously (just under the skin). By using rHuPH20, some biologics and compounds that are administered ...